Last Updated: 6 February 2025
COEPTIS, a leader in biotechnology and artificial intelligence, announced the successful closure of its Series A Preferred Offering, securing an additional $5.7 million and bringing the total to $10 million.
Led by CJC Investment Trust and supported by board member Christopher Calise, the round highlights strong investor confidence in COEPTIS' innovative healthcare strategies.
The proceeds are designated for enhancing the company's balance sheet, repaying debts, and supporting overall corporate activities.
The additional funds will also accelerate the integration of advanced AI solutions and automation technologies, improving both research and operational efficiency across COEPTIS.
"We're thrilled to announce the successful closure of our second Series A Preferred financing. This funding is pivotal as we expand our operational capabilities and enhance shareholder value through our new Technology Division."
Brian Cogley, CFO of COEPTIS
The incorporation of AI technology from the recent acquisition of the NexGenAI Affiliates Network platform is set to revolutionize their approach to marketing and operations.
COEPTIS is dedicated to developing cell therapy platforms for cancer, autoimmune, and infectious diseases.
Their efforts are bolstered by assets licensed from Deverra Therapeutics, including a cutting-edge cellular immunotherapy platform and DVX201, a clinical-stage natural killer cell therapy.
In collaboration with VyGen-Bio and top medical researchers at the Karolinska Institute, COEPTIS is pushing the boundaries of biopharmaceutical technology.
The company has also recently set up a Technology Division focused on enhancing operational capabilities through AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group. Based in Wexford, PA, COEPTIS remains committed to meeting FDA regulatory standards and ensuring high compliance and patient care.
"This additional financing enables Coeptis to not just fortify its mission in cell therapy but also empowers us to drive innovation in technology and AI," added Dave Mehalick, President and CEO of COEPTIS. "By fostering a culture of responsible innovation, we aim to capitalize on diverse growth opportunities, creating a self-sustaining business model that establishes a strong foundation for long-term success and profitability."
Dave Mehalick, President and CEO of COEPTIS
The recent completion of COEPTIS, Inc.'s Series A Preferred Offering, which successfully raised an additional $5.7 million to reach a total of $10 million, showcases strong investor confidence, notably with significant backing from board member Christopher Calise through CJC Investment Trust.
This funding supports strategic initiatives and expands COEPTIS’ portfolio with stakes in new subsidiaries, SNAP Biosciences and GEAR Therapeutics, aligning with the company’s focus on innovation and growth in biotechnology.
